Trial Profile
A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Dacarbazine
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms SUAVE
- 27 Oct 2019 Status changed from discontinued to completed.
- 15 Nov 2017 Planned End Date changed from 1 Nov 2016 to 8 Nov 2012.
- 15 Nov 2017 Status changed from active, no longer recruiting to discontinued.